1. Lacroix J, Leuchs B, Li J, Hristov G, Deubzer HE, Kulozik AE, Witt O, Rommelaere J: Parvovirus H1 selectivity induces cytotoxic effects on human neuroblastoma cells. 2010, 1239:1230-1239.
2. Ahmad U, Ahmed I, Keong YY, Abd Manan N, Othman F: Inhibitory and apoptosis-inducing effects of Newcastle disease virus strain AF2240 on mammary carcinoma cell line. Biomed Res Int2015, 2015:127828.
3. Chellappa MM, Dey S, Gaikwad S, Kataria M, Vakharia VN, Kataria JM: Complete genome sequence of Newcastle disease virus mesogenic vaccine strain R2B from India. Journal of virology2012, 86:13814-13815.
4. de Leeuw O, Peeters B: Complete nucleotide sequence of Newcastle disease virus: evidence for the existence of a new genus within the subfamily Paramyxovirinae. The Journal of general virology1999, 80 ( Pt 1):131-136.
5. Phillips RJ, Samson AC, Emmerson PT: Nucleotide sequence of the 5'-terminus of Newcastle disease virus and assembly of the complete genomic sequence: agreement with the "rule of six". Archives of virology1998, 143:1993-2002.
6. Steward M, Samson AC, Errington W, Emmerson PT: The Newcastle disease virus V protein binds zinc. Archives of virology1995, 140:1321-1328.
7. Steward M, Vipond IB, Millar NS, Emmerson PT: RNA editing in Newcastle disease virus. The Journal of general virology1993, 74 ( Pt 12:2539-2547.
8. Ravindra PV, Tiwari AK, Ratta B, Bais MV, Chaturvedi U, Palia SK, Sharma B, Chauhan RS: Time course of Newcastle disease virus-induced apoptotic pathways. Virus Res2009, 144:350-354.
9. Kumar R, Tiwari AK, Chaturvedi U, Kumar GR, Sahoo AP, Rajmani RS, Saxena L, Saxena S, Tiwari S, Kumar S: Velogenic Newcastle Disease Virus as an Oncolytic Virotherapeutics: In Vitro Characterization. vol. 167. pp. 2005-2022; 2012:2005-2022.
10. Scheid A, Choppin PW: Isolation and purification of the envelope proteins of Newcastle disease virus. Journal of virology1973, 11:263-271.
11. Seal BS, King DJ, Sellers HS: The avian response to Newcastle disease virus. vol. 24. pp. 257-268; 2000:257-268.
12. Murawski MR, McGinnes LW, Finberg RW, Kurt-Jones EA, Massare MJ, Smith G, Heaton PM, Fraire AE, Morrison TG: Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology. J Virol2010, 84:1110-1123.
13. Zamarin D, Palese P: Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions. Future Microbiol2012, 7:347-367.
14. Park M-S, García-Sastre A, Cros JF, Basler CF, Palese P: Newcastle disease virus V protein is a determinant of host range restriction. Journal of virology2003, 77:9522-9532.
15. Lam HY, Yusoff K, Yeap SK, Subramani T, Abd-aziz S: Immunomodulatory Effects of Newcastle Disease Virus AF2240 Strain on Human Peripheral Blood Mononu- clear Cells. 2014, 11:6-13.
16. Schirrmacher V, Ahlert T, Pröbstle T, Steiner HH, Herold-Mende C, Gerhards R, Hagmüller E: Immunization with virus-modified tumor cells. Seminars in oncology1998, 25:677-696.
17. Schirrmacher V, Griesbach A, Ahlert T: Antitumor effects of Newcastle Disease Virus in vivo: local versus systemic effects. vol. 18. pp. 945-952; 2001:945-952.
18. Csatary LK, Gosztonyi G, Szeberenyi J, Fabian Z, Liszka V, Bodey B, Csatary CM: MTH-68/H oncolytic viral treatment in human high-grade gliomas. Journal of neuro-oncology2003, 67:83-93.
19. Yaacov B, Eliahoo E, Elihaoo E, Lazar I, Ben-Shlomo M, Greenbaum I, Panet a, Zakay-Rones Z: Selective oncolytic effect of an attenuated Newcastle disease virus (NDV-HUJ) in lung tumors. Cancer gene therapy2008, 15:795-807.
20. Walter RJ, Attar BM, Delimata M, Tejaswi S, Hepatology G, H CCJ: JOP . Journal of the Two Avirulent , Lentogenic Strains of. 2012:1-23.
21. Ali R, Alabsi AM, Ali AM, Ideris A, Omar AR, Yusoff K, Saif-Ali R: Cytolytic effects and apoptosis induction of Newcastle disease virus strain AF2240 on anaplastic astrocytoma brain tumor cell line. Neurochem Res2011, 36:2051-2062.
22. Alabsi AM, Bakar SAA, Ali R, Omar AR, Bejo MH, Ideris A, Ali AM: Effects of newcastle disease virus strains AF2240 and V4-UPM on cytolysis and apoptosis of leukemia cell lines. International journal of molecular sciences2011, 12:8645-8660.
23. Chia S-L, Yusoff K, Shafee N: Viral persistence in colorectal cancer cells infected by Newcastle disease virus. Virology journal2014, 11.
24. Freeman AI, Zakay-Rones Z, Gomori JM, Linetsky E, Rasooly L, Greenbaum E, Rozenman-Yair S, Panet A, Libson E, Irving CS, et al: Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther2006, 13:221-228.
25. Csatary LK, Eckhardt S, Bukosza I, Czegledi F, Fenyvesi C, Gergely P, Bodey B, Csatary CM: Attenuated veterinary virus vaccine for the treatment of cancer. Cancer Detect Prev1993, 17:619-627.
26. Kirchner HH, Anton P, Atzpodien J: Adjuvant treatment of locally advanced renal cancer with autologous virus-modified tumor vaccines. World J Urol1995, 13:171-173.
27. Batliwalla FM, Bateman BA, Serrano D, Murray D, Macphail S, Maino VC, Ansel JC, Gregersen PK, Armstrong CA: A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire. Mol Med1998, 4:783-794.
28. Cassel WA, Murray DR: A ten-year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate. Med Oncol Tumor Pharmacother1992, 9:169-171.
29. Rangaswamy US, Wang W, Cheng X, McTamney P, Carroll D, Jin H: Newcastle Disease Virus Establishes Persistent Infection in Tumor Cells In Vitro: Contribution of the Cleavage Site of Fusion Protein and Second Sialic Acid Binding Site of Hemagglutinin-Neuraminidase. J Virol2017, 91.
30. Yeung KY, Ruzzo WL: An empirical study on principal component analysis for clustering gene expression data. Bioinformatics2001, 17:763-774.
31. Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B: Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nature methods2008, 5:621.
32. Love MI, Huber W, Anders S: Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome biology2014, 15:550.
33. Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, Benner C, Chanda SK: Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun2019, 10:1523.
34. Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov JP, Tamayo P: The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst2015, 1:417-425.
35. Sergushichev A: An algorithm for fast preranked gene set enrichment analysis using cumulative statistic calculation. BioRxiv2016:060012.
36. Katafiasz BJ, Nieman MT, Wheelock MJ, Johnson KR: Characterization of cadherin-24, a novel alternatively spliced type II cadherin. Journal of Biological Chemistry2003, 278:27513-27519.
37. Takeichi M: Morphogenetic roles of classic cadherins. Current opinion in cell biology1995, 7:619-627.
38. Takeichi M: The cadherin cell adhesion receptor family: roles in multicellular organization and neurogenesis. Progress in clinical and biological research1994, 390:145-153.
39. Wheelock MJ, Soler AP, Knudsen KA: Cadherin junctions in mammary tumors. Journal of mammary gland biology and neoplasia2001, 6:275-285.
40. Hajra KM, Fearon ER: Cadherin and catenin alterations in human cancer. Genes, Chromosomes and Cancer2002, 34:255-268.
41. Thiery JP: Epithelial–mesenchymal transitions in tumour progression. Nature Reviews Cancer2002, 2:442.
42. Matthews JD, Morgan R, Sleigher C, Frey TK: Do viruses require the cytoskeleton? Virology journal2013, 10:121.
43. Syrigos KN, Harrington KJ, Karayiannakis AJ, Sekara E, Chatziyianni E, Syrigou EI, Waxman J: Clinical significance of heat shock protein-70 expression in bladder cancer. Urology2003, 61:677-680.
44. Kawai T, Enomoto Y, Morikawa T, Matsushita H, Kume H, Fukayama M, Yamaguchi H, Kakimi K, Homma Y: High expression of heat shock protein 105 predicts a favorable prognosis for patients with urinary bladder cancer treated with radical cystectomy. Molecular and clinical oncology2014, 2:38-42.
45. Ischia J, So AI: The role of heat shock proteins in bladder cancer. Nature Reviews Urology2013, 10:386.
46. Daza J, Gul Z, Sfakianos JP: Role of heat shock proteins in bladder cancer: potential biomarkers for treatment response and oncological prognosis. Translational Andrology and Urology2019.
47. Taylor HS, Vanden Heuvel GB, Igarashi P: A conserved Hox axis in the mouse and human female reproductive system: late establishment and persistent adult expression of the Hoxa cluster genes. Biology of reproduction1997, 57:1338-1345.
48. Goodman FR: Limb malformations and the human HOX genes. American journal of medical genetics2002, 112:256-265.
49. Sun Y, Zhou B, Mao F, Xu J, Miao H, Zou Z, Jang Y, Cai S, Witkin M, Koche R: HOXA9 reprograms the enhancer landscape to promote leukemogenesis. Cancer cell2018, 34:643-658. e645.
50. Gilbert PM, Mouw JK, Unger MA, Lakins JN, Gbegnon MK, Clemmer VB, Benezra M, Licht JD, Boudreau NJ, Tsai KK: HOXA9 regulates BRCA1 expression to modulate human breast tumor phenotype. The Journal of clinical investigation2010, 120:1535-1550.
51. Dolle P, Izpisua-Belmonte J, Brown J, Tickle C, Duboule D: HOX-4 genes and the morphogenesis of mammalian genitalia. Genes & Development1991, 5:1767-1776.
52. Brechka H, Bhanvadia RR, VanOpstall C, Vander Griend DJ: HOXB13 mutations and binding partners in prostate development and cancer: Function, clinical significance, and future directions. Genes & diseases2017, 4:75-87.
53. Bishnoi S, Tiwari R, Gupta S, Byrareddy S, Nayak D: Oncotargeting by vesicular stomatitis virus (VSV): advances in cancer therapy. Viruses2018, 10:90.
54. Lyles DS: Cytopathogenesis and inhibition of host gene expression by RNA viruses. Microbiol Mol Biol Rev2000, 64:709-724.
55. Lan D, Tang C, Li M, Yue H: Screening and identification of differentially expressed genes from chickens infected with Newcastle disease virus by suppression subtractive hybridization. Avian pathology2010, 39:151-159.
56. Benchimol S: p53-dependent pathways of apoptosis. Nature Publishing Group; 2001.
57. Bahk YY, Lee J, Cho I-H, Lee H-W: An analysis of an interactome for apoptosis factor, Ei24/PIG8, using the inducible expression system and shotgun proteomics. Journal of proteome research2010, 9:5270-5283.
58. Fu M, Maresh EL, Soslow RA, Alavi M, Mah V, Zhou Q, Iasonos A, Goodglick L, Gordon LK, Braun J: Epithelial membrane protein-2 is a novel therapeutic target in ovarian cancer. Clinical Cancer Research2010, 16:3954-3963.
59. Qin Y, Fu M, Takahashi M, Iwanami A, Kuga D, Rao RG, Sudhakar D, Huang T, Kiyohara M, Torres K: Epithelial membrane protein-2 (EMP2) activates Src protein and is a novel therapeutic target for glioblastoma. Journal of Biological Chemistry2014, 289:13974-13985.
60. Amin MKBA, Shimizu A, Zankov DP, Sato A, Kurita S, Ito M, Maeda T, Yoshida T, Sakaue T, Higashiyama S: Epithelial membrane protein 1 promotes tumor metastasis by enhancing cell migration via copine-III and Rac1. Oncogene2018, 37:5416.
61. Hafner A, Bulyk ML, Jambhekar A, Lahav G: The multiple mechanisms that regulate p53 activity and cell fate. Nature reviews Molecular cell biology2019, 20:199-210.
62. He L, Vasiliou K, Nebert DW: Analysis and update of the human solute carrier (SLC) gene superfamily. Human genomics2009, 3:195.
63. Hediger MA, Romero MF, Peng J-B, Rolfs A, Takanaga H, Bruford EA: The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteins. Pflügers Archiv2004, 447:465-468.
64. Chin CL: Transcriptomic Analysis of Persistently NDV Infected bladder cancer cellsUniversiti Putra Malaysia Genetics Engineering 2018.
65. Hazan RB, Qiao R, Keren R, Badano I, Suyama K: Cadherin switch in tumor progression. Annals of the New York Academy of Sciences2004, 1014:155-163.
66. Wheelock MJ, Shintani Y, Maeda M, Fukumoto Y, Johnson KR: Cadherin switching. J Cell Sci2008, 121:727-735.
67. van der Horst G, Bos L, van der Mark M, Cheung H, Heckmann B, Clement-Lacroix P, Lorenzon G, Pelger RC, Bevers RF, van der Pluijm G: Targeting of alpha-v integrins reduces malignancy of bladder carcinoma. PloS one2014, 9:e108464.
68. Yang H, Wang L, Zhao J, Chen Y, Lei Z, Liu X, Xia W, Guo L, Zhang H-T: TGF-β-activated SMAD3/4 complex transcriptionally upregulates N-cadherin expression in non-small cell lung cancer. Lung Cancer2015, 87:249-257.
69. Bittner M, Meltzer P, Chen Y, Jiang Y, Seftor E, Hendrix M, Radmacher M, Simon R, Yakhini Z, Ben-Dor A: Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature2000, 406:536.
70. Hendrix MJ, Seftor EA, Meltzer PS, Gardner LM, Hess AR, Kirschmann DA, Schatteman GC, Seftor RE: Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry. Proceedings of the National Academy of Sciences2001, 98:8018-8023.
71. Aishah S, Bakar A, Zawawi M, Ali AM, Ideris A: Induction of Apoptosis by Newcastle Disease Virus Strains AF220 and V4-UPM in Human Promyelocytic Leukemia (HL60) and Human T- Lymphoblastic Leukemia (CEM-SS) Cells. International Journal of Medical and Biological Sciences2012, 6:209-213.
72. Ali R, Alabsi AM, Ali AM, Ideris A, Omar AR, Yusoff K, Saif-Ali R: Cytolytic effects and apoptosis induction of newcastle disease virus strain AF2240 on anaplastic astrocytoma brain tumor cell line. Neurochemical Research2011, 36:2051-2062.
73. Ghrici M, El Zowalaty M, Omar AR, Ideris A: Newcastle disease virus Malaysian strain AF2240 induces apoptosis in MCF-7 human breast carcinoma cells at an early stage of the virus life cycle. International Journal of Molecular Medicine2013, 31.
74. Kang Y, Yuan R, Xiang B, Zhao X, Gao P, Dai X, Liao M, Ren T: Newcastle disease virus-induced autophagy mediates antiapoptotic signaling responses in vitro and in vivo. Oncotarget2017, 8:73981.
75. Assayaghi RM, Alabsi AM, Ali AM: Apoptosis induction of newcastle disease virus strains (AF 2240 & V4-UPM) on HT-29Human colorectal adenocarcinoma cells. J Cancer Res2016, 4:101.
76. Elankumaran S, Rockemann D, Samal SK: Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell death. Journal of virology2006, 80:7522-7534.
77. Meng C, Zhou Z, Jiang K, Yu S, Jia L, Wu Y, Liu Y, Meng S, Ding C: Newcastle disease virus triggers autophagy in U251 glioma cells to enhance virus replication. Archives of virology2012, 157:1011-1018.
78. Sun Y, Yu S, Ding N, Meng C, Meng S, Zhang S, Zhan Y, Qiu X, Tan L, Chen H: Autophagy benefits the replication of Newcastle disease virus in chicken cells and tissues. Journal of virology2014, 88:525-537.
79. Keshavarz M, Solaymani-Mohammadi F, Miri SM, Ghaemi A: Oncolytic paramyxoviruses-induced autophagy; a prudent weapon for cancer therapy. Journal of biomedical science2019, 26:48.
80. Lee Y-R, Kuo S-H, Lin C-Y, Fu P-J, Lin Y-S, Yeh T-M, Liu H-S: Dengue virus-induced ER stress is required for autophagy activation, viral replication, and pathogenesis both in vitro and in vivo. Scientific reports2018, 8:489.
81. Iranpour M, Moghadam AR, Yazdi M, Ande SR, Alizadeh J, Wiechec E, Lindsay R, Drebot M, Coombs KM, Ghavami S: Apoptosis, autophagy and unfolded protein response pathways in Arbovirus replication and pathogenesis. Expert reviews in molecular medicine2016, 18.
82. Chaurushiya MS, Weitzman MD: Viral manipulation of DNA repair and cell cycle checkpoints. DNA repair2009, 8:1166-1176.
83. Takahashi T, Suzuki T: Function of membrane rafts in viral lifecycles and host cellular response. Biochemistry research international2011, 2011.
84. Jennings MT, Pietenpol JA: The role of transforming growth factor β in glioma progression. Journal of neuro-oncology1998, 36:123-140.
85. Fabregat I, Fernando J, Mainez J, Sancho P: TGF-beta signaling in cancer treatment. Current pharmaceutical design2014, 20:2934-2947.
86. Fournier P, Arnold A, Wilden H, Schirrmacher V: Newcastle disease virus induces pro-inflammatory conditions and type I interferon for counter-acting Treg activity. International journal of oncology2012, 40:840-850.
87. Elankumaran S, Chavan V, Qiao D, Shobana R, Moorkanat G, Biswas M, Samal SK: Type I interferon-sensitive recombinant Newcastle disease virus for oncolytic virotherapy. Journal of virology2010, 84:3835-3844.
88. Zamarin D, Holmgaard RB, Subudhi SK, Park JS, Mansour M, Palese P, Merghoub T, Wolchok JD, Allison JP: Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Science translational medicine2014, 6:226ra232-226ra232.
89. Ginting TE, Suryatenggara J, Christian S, Mathew G: Proinflammatory response induced by Newcastle disease virus in tumor and normal cells. Oncolytic virotherapy2017, 6:21.
90. Chang S, Liu J, Guo S, He S, Qiu G, Lu J, Wang J, Fan L, Zhao W, Che X: HOTTIP and HOXA13 are oncogenes associated with gastric cancer progression. Oncology reports2016, 35:3577-3585.
91. Duan R, Han L, Wang Q, Wei J, Chen L, Zhang J, Kang C, Wang L: HOXA13 is a potential GBM diagnostic marker and promotes glioma invasion by activating the Wnt and TGF-β pathways. Oncotarget2015, 6:27778.
92. Ewing CM, Ray AM, Lange EM, Zuhlke KA, Robbins CM, Tembe WD, Wiley KE, Isaacs SD, Johng D, Wang Y: Germline mutations in HOXB13 and prostate-cancer risk. New England Journal of Medicine2012, 366:141-149.
93. Marra L, Cantile M, Scognamiglio G, Perdonà S, La Mantia E, Cerrone M, Gigantino V, Cillo C, Caraglia M, Pignata S: Deregulation of HOX B13 expression in urinary bladder cancer progression. Current medicinal chemistry2013, 20:833-839.
94. Li B, Huang Q, Wei G-H: The Role of HOX Transcription Factors in Cancer Predisposition and Progression. Cancers2019, 11:528.
95. Hu H, Chen Y, Cheng S, Li G, Zhang Z: Dysregulated expression of homebox gene HOXA13 is correlated with the poor prognosis in bladder cancer. Wiener Klinische Wochenschrift2017, 129:391-397.
96. Shelokov A, Vogel JE, Chi L: Hemadsorption (adsorption-hemagglutination) test for viral agents in tissue culture with special reference to influenza. Proceedings of the Society for Experimental Biology and Medicine1958, 97:802-809.
97. Chambers P, Samson AC: A new structural protein for Newcastle disease virus. J Gen Virol1980, 50:155-166.
98. Andrews S: FastQC: a quality control tool for high throughput sequence data. Babraham Bioinformatics, Babraham Institute, Cambridge, United Kingdom; 2010.
99. Ewels P, Magnusson M, Lundin S, Käller M: MultiQC: summarize analysis results for multiple tools and samples in a single report. Bioinformatics2016, 32:3047-3048.
100. Pertea M, Kim D, Pertea GM, Leek JT, Salzberg SL: Transcript-level expression analysis of RNA-seq experiments with HISAT, StringTie and Ballgown. Nature protocols2016, 11:1650.
101. Flicek P, Ahmed I, Amode MR, Barrell D, Beal K, Brent S, Carvalho-Silva D, Clapham P, Coates G, Fairley S, et al: Ensembl 2013. Nucleic acids research2013, 41:D48-D55.
102. Pertea M, Pertea GM, Antonescu CM, Chang T-C, Mendell JT, Salzberg SL: StringTie enables improved reconstruction of a transcriptome from RNA-seq reads. Nature biotechnology2015, 33:290.
103. Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C: Salmon provides fast and bias-aware quantification of transcript expression. Nature methods2017, 14:417.
104. Korotkevich G, Sukhov V, Sergushichev A: Fast gene set enrichment analysis. bioRxiv2019:060012.
105. Liberzon A, Subramanian A, Pinchback R, Thorvaldsdóttir H, Tamayo P, Mesirov JP: Molecular signatures database (MSigDB) 3.0. Bioinformatics2011, 27:1739-1740.
106. Flicek P, Amode MR, Barrell D, Beal K, Billis K, Brent S, Carvalho-Silva D, Clapham P, Coates G, Fitzgerald S: Ensembl 2014. Nucleic acids research2013, 42:D749-D755.
107. Team RC: R: A language and environment for statistical computing. 2013.